Abstract:Objective:To evaluate 8-week effects and adverse reactions of infliximab in patients with severe refractory rheumatoid arthritis(RA).Methods: Ten patients with severe refractory RA were treated with infliximab(weeks 0,2 and 6),and clinical,laboratory and psychological indices were recorded 1,4,and 8 weeks after treatment.Results: The clinical,laboratory indices and DAS28 score observed in all of the patients were significantly improved(P<0.05),and no obvious adverse reactions were observed.Conclusion: Infliximab can quickly relieve the symptoms and the activated conditions of severe refractory RA within few weeks.

Clinical research of infliximab in patients with severe refractory rheumatoid arthritis